Document Detail

FGF-23 and vitamin D: don't shoot the messenger?
MedLine Citation:
PMID:  22523113     Owner:  NLM     Status:  MEDLINE    
The discovery of fibroblast growth factor-23 (FGF-23) as a key regulator of phosphate and vitamin D metabolism has forced a rethink about the mineral and bone disorder of chronic kidney disease (CKD). FGF-23 powerfully predicts adverse cardiovascular outcomes in patients with CKD and an important question is whether treatment regimens should now be tailored to address FGF-23 levels in addition to those of calcium, phosphate, parathyroid hormone and vitamin D. Nevertheless, despite the known action of active vitamin D therapies to increase FGF-23, this should probably still form an important part of the management of patients with hyperparathyroidism and perhaps at low doses of essentially all patients with advanced renal disease.
Richard S Fish; John Cunningham
Related Documents :
53603 - Gastric function in chronic renal failure. effects of maintenance haemodialysis.
8731953 - Study of gastric and gallbladder kinetics with real-time ultrasonography in cases of fu...
3203293 - Breakpoint zone of bcr in chronic myelogenous leukemia does not correlate with disease ...
Publication Detail:
Type:  Comment; Editorial     Date:  2012-04-20
Journal Detail:
Title:  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association     Volume:  27     ISSN:  1460-2385     ISO Abbreviation:  Nephrol. Dial. Transplant.     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-05-31     Completed Date:  2012-10-02     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8706402     Medline TA:  Nephrol Dial Transplant     Country:  England    
Other Details:
Languages:  eng     Pagination:  2137-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Density Conservation Agents / therapeutic use*
Ergocalciferols / therapeutic use*
Fibroblast Growth Factors / metabolism*
Hydroxycholecalciferols / therapeutic use*
Hyperparathyroidism, Secondary / drug therapy*,  metabolism*
Reg. No./Substance:
0/Bone Density Conservation Agents; 0/Ergocalciferols; 0/Hydroxycholecalciferols; 0/fibroblast growth factor 23; 131918-61-1/paricalcitol; 62031-54-3/Fibroblast Growth Factors; URQ2517572/alfacalcidol
Comment On:
Nephrol Dial Transplant. 2012 Jun;27(6):2263-9   [PMID:  22140123 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Association of IRS-1 and IRS-2 genes polymorphisms with polycystic ovary syndrome: a meta-analysis.
Next Document:  Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects...